AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03528395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-immersive virtual reality
Description: Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
Study NCT03528395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
Study NCT04340427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3455
Description: TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
Study NCT05683431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control of Emotion (CCE) Training
Description: Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
Study NCT04516837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag 25-75 mg oral daily according to platelet response.
Study NCT04516837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 25-75 mg oral daily according to platelet response.
Study NCT04516837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Study NCT02994888 — intervention group
Intervention type: DRUG
Intervention: Cetuximab
Description: All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
Study NCT02793843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Zofran)
Description: Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
Study NCT02793843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (Zofran)
Description: Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
Study NCT02793843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Decadron)
Description: Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
Study NCT02793843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
Study NCT04111419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET
Description: amlodipine/atorvastatin (5/20mg tablet) once a day
Study NCT04111419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET
Description: amlodipine/atorvastatin (5/10mg tablet) once a day
Study NCT04111419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil
Description: allisartan (240mg/tablet) once a day
Study NCT04111419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: allisartan (240mg/tablet) once a day
Study NCT03143686 — intervention group
Intervention type: DEVICE
Intervention: ACURATE TA™ Transapical Aortic Bioprosthesis
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
Study NCT03513731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cell injection
Description: ADRC injection into the facet joint
Study NCT03513731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Corticosteroid injection into the facet joint
Study NCT02393885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Study NCT02618083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: color Doppler ultrasound
Description: pre-operative blood flow velocity measurement with a color Doppler ultrasound device
Study NCT00073307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multi Kinase Inhibitor
Study NCT00073307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02793843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
Study NCT02547883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cessation of statin
Description: The intervention evaluated is the cessation of statin
Study NCT00912379 — intervention group
Intervention type: BIOLOGICAL
Intervention: hemoglobin determination
Description: laboratory and non invasive hemoglobin determinations
Study NCT00031395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine is FDA-approved for the treatment of hypertension in adults.
Study NCT00031395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: MPH is FDA-approved for the treatment of ADHD symptoms in children.
Study NCT00031395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT02409355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
Study NCT02409355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
Study NCT02409355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at 75 milligrams per square meter (mg/m\^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
Study NCT02409355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1000 mg/m\^2 (when coadministered with carboplatin) or 1250 mg/m\^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
Study NCT03306394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil hydrochloride (S95005)
Study NCT04123080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation assisted polypectomy
Description: A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
Study NCT04564560 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular aortic repair with Zenith Alpha Spiral-Z®
Description: The Zenith Alpha Spiral-Z® stent graft may have an increased risk of thrombosis. The intervention in this study is to assess the extent and degree of thrombosis in patients treated with the Zenith Alpha Spiral-Z® during endovascular repair of aortic aneurysm
Study NCT00987103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
Study NCT04368247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Fluorescent Imaging
Description: Application of reagents, then imaging and scoring
Study NCT01437800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride / Extended release Metformin (4/850 mg).
Description: One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
Study NCT04631991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive ophthalmologic examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
Study NCT04630327 — intervention group
Intervention type: OTHER
Intervention: Beck Depression Inventory-21 (diagnostic survey)
Description: Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
Study NCT04630327 — intervention group
Intervention type: OTHER
Intervention: Beck Anxiety Inventory
Description: Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
Study NCT04630327 — intervention group
Intervention type: OTHER
Intervention: Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria
Description: Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
Study NCT00760825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed bivalent (O1 and O139)whole cell oral cholera vaccine
Description: 1.5 ml given twice orally, 14 days apart
Study NCT00002831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered orally every 6 hours on consecutive days -6 through -4.
Study NCT00002831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
Study NCT03248895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Direct Observation of Therapy (MDOT)
Description: Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
Study NCT00598403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefditoren pivoxil
Description: 400 mg, oral, single dose during 3 days
Study NCT00598403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: 250 mg, oral, twice a day for 3 days
Study NCT04433598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Intervention
Description: Each participant were interviewed by face- to- face using Arabic language, after 1 hour when they finish their assessment by medical doctors. The researcher was collected the data from the participants in a special room for 10-15 minutes, after only one hour of completing the necessary tests with the treating physician to allow participants to go for a meal before the nutrition education starts.12 classes (1:30 hour each session):- 100 participants / 5 days = 20 participants each class was offered twice per day to cover the number of participants and to enhance attendance for them can not attend at first morning. the classes was designed according to health belief model (HBM). The topics were about the type 2 diabetes and its complications,the benefits of diabetes plate and eating vegetables before carbohydrates.
Study NCT00621530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine opthalmic solution
Description: ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
Study NCT00621530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be added to the patient's routine spinal anesthetic for surgery
Study NCT01514370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta 1a 44 mcg TIW
Description: Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
Study NCT00330018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir
Study NCT00330018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Acyclovir
Study NCT01514370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IFN beta 1a 44 mcg TIW
Description: Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
Study NCT01514370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
Study NCT01514370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo matched to curcumin orally twice a day for 24 months.
Study NCT04046588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Infrared thermography
Description: A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
Study NCT04046588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian.
Study NCT03113955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem Microsphere loaded with Epirubicin
Description: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
Study NCT02470572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnyx™ IDP system
Description: Omnyx™ IDP system for Whole Slide Images (WSI)
Study NCT01551420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced upper limb prosthetic device IMU controlled
Description: Advanced upper limb prosthetic IMU controlled
Study NCT01551420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced upper limb prosthetic EMG-PR controlled
Description: Advanced upper limb prosthetic EMG-PR controlled
Study NCT03612856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB023- Dose 1
Description: Participants will receive a single dose of 0.25 mg/kg AB023.
Study NCT03612856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB023-Dose 2
Description: Participants will receive a single dose of 0.5 mg/kg AB023.
Study NCT03612856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a single dose of placebo.
Study NCT00219544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: pregabalin 150mg/day (75mg BID)
Study NCT00219544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: pregabalin 300 mg/day (150mg BID)
Study NCT00219544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: pregabalin 600/day (300mg BID)
Study NCT00219544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05635188 — intervention group
Intervention type: PROCEDURE
Intervention: Intestinal ostomy confection
Description: Surgical procedure for fecal diverting
Study NCT00624702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol maleate
Description: Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Study NCT00624702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04616742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SHR6390
Description: Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
Study NCT01739855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calciferol, calcium carbonate
Study NCT02980796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
Study NCT02470572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional light microscope
Description: Conventional light microscope
Study NCT01485835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
Study NCT01485835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
Study NCT01485835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
Study NCT02772588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Study NCT02772588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Study NCT02772588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Study NCT02772588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic, ultra-fractionated radiotherapy
Study NCT03884036 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamine D
Study NCT03884036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamine D
Study NCT02063269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: 9-18mg/rivastigmine for 52 weeks
Study NCT03473197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diacerein 1% ointment
Description: During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
Study NCT00267670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg PO TID
Study NCT00267670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill PO TID
Study NCT04919161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight support system control group
Description: The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.